• br APJ expression in metabolic diseases

  2023-10-19

  

  APJ expression in metabolic diseases Under physiological conditions, APJ is present in humans as well as in mouse tissues with high metabolic activity such as muscle and adipose tissue but not in the liver. Moreover, the presence and regulation of APJ in established adipocyte or muscle cell lines

• br Acknowledgments br Protein microarrays were developed to

  2023-10-19

  

  Acknowledgments Protein microarrays were developed to provide miniaturized high-throughput tools to study protein function, 4945 and post-translational modifications. Just a few years ago, the seminal work performed in Stuart Schreiber's laboratory at Harvard University () and at Michael Snyde

• Regardless of the initial treatment most patients with advan

  2023-10-18

  

  Regardless of the initial treatment, most patients with advanced NSCLC experience relapse and disease progression [15]. A subpopulation of immediate concern and clinical need is patients who have advanced NSCLC that is especially aggressive, which is usually defined as disease that rapidly progresse

• The loss of synaptic proteins such as synaptophysin from

  2023-10-18

  

  The loss of synaptic proteins such as synaptophysin from the Olanzapine is indicative of synapse degeneration and provided a good correlate of the degree of dementia in AD [12], [13], [14]. Consequently, the loss of synaptic proteins from cultured primary neurons incubated with Aβ provides a useful

• br Applications of ATN in clinical trials In pivotal trials

  2023-10-18

  

  Applications of ATN in clinical trials In pivotal trials, the use of biomarkers will also have to be considered in the context of regulatory risk and scrutiny. Although an important intended application of the framework is in research studies, its use will undoubtedly impact clinical development

• PFI-2 Both subcutaneous s c and mucosal administration of

  2023-10-18

  

  Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel

• br Conclusion Biotransformation of trachyloban

  2023-10-18

  

  Conclusion Biotransformation of trachyloban-19-oic Phenformin by S. racemosum provided three products. Oxidation of compound 1 at C-17 (2–3), as well as rearrangement of 1 into a kaurane diterpene hydroxylated in C-16 and C-17 (4) were crucial for increasing AChE inhibitory activity. Compound 3

• br ARIs in the prevention of prostate cancer Prostate cancer

  2023-10-18

  

  5ARIs in the prevention of prostate cancer Prostate cancer continues to be a leading cause of male deaths worldwide. In 2009, it was estimated there would be 192,280 new cases of prostate cancer with a predicted 27,360 deaths [25]. Because androgens, and specifically DHT, play a large role in bot

• br Conclusion Growth survival and invasion of

  2023-10-18

  

  Conclusion Growth, survival, and invasion of most PCs have been shown to be androgen-dependent at the onset of castration therapy [31]. Thus, castration therapy has been central to systemic therapy and remains the standard approach to PC treatment. Even after progression to a castration-resistant

• Citral or dimethyl octadien al

  2023-10-18

  

  Citral or 3,7-dimethyl-2,6-octadien-1-al is a mixture of two stereoisomeric monoterpene aldehydes (the trans isomer geranial, citral A (40–62%)) and the cis isomer neral, citral B (25–38%) and serves one of the main constituent of essential oils of C. citratusis used in cosmetic, food, fungicides, p

• br Introduction Sustained over activation of neurohormonal s

  2023-10-17

  

  Introduction Sustained over-activation of neurohormonal systems is a hallmark in the pathophysiology of cardiac dysfunction following myocardial infarction (MI) and heart failure (HF). Inhibitors of the renin-angiotensin CRT 0066101 system (RAAS) constitute cornerstones of pharmacotherapy for HF

• br Conflict of interest statement br Introduction Currently

  2023-10-17

  

  Conflict of interest statement Introduction Currently, adenocarcinoma is the most common histological subtype of lung cancer. Activating mutations and translocations with a potential for targeted therapy are reported predominantly in non-smokers. ALK rearrangement is found in less than 5% of u

• The decreased AR mediated response has been attributed to

  2023-10-17

  

  The decreased βAR-mediated response has been attributed to different mechanisms, including an attenuation of PKA activation, an impaired generation of cyclic AMP, a reduced receptor density, and a less efficient coupling to adenylyl-cyclase [10]. However, currently there is no single molecular or ce

• euk 134 Two cell surface trans membrane receptors

  2023-10-17

  

  Two cell-surface trans-membrane receptors have been identified for adiponectin, AdipoR1 and AdipoR2 [21], and adiponectin action is known to signal through these receptors and the docking protein APPL1 [22]. In muscle and liver cells, signal transduction involves the phosphorylation and activation o

• br Conflict of interest statement br Benign prostatic hyperp

  2023-10-17

  

  Conflict of interest statement Benign prostatic hyperplasia (BPH) is a highly complex process characterized by an increased number of epithelial and stromal PF-573228 in the transition zone. , , Autopsy studies by McNeal detail the evolution of histological changes within these 2 cellular com

14916 records 214/995 page Previous Next First page 上5页 211212213214215 下5页 Last page